Composition for treating metastatic solid cancer, comprising TSG6 inhibitor
AssigneeIndustry-University Cooperation Foundation Hanyang University Erica Campus
InventorsHyung Shin Yim, Sol-Bi Shin, Hay-Ran Jang
Life of this patent
Estimating the term…
Abstract
The present invention relates to a use of TSG6 shRNA as a therapeutic agent for metastatic solid cancer. More specifically, the present invention can be usefully used for treating cancer in which metastasis occurs by PLK1, which is known to be overexpressed, particularly in cancer, and the active form thereof or TGF-beta/Smad signaling by reducing proliferation, migration, and invasiveness of metastatic cancer cells through gene therapy that suppresses TSG6 mRNA expression.
Claims6
A composition for treating metastatic solid cancer, comprising a tumor necrosis factor-inducible gene 6 protein (TSG6) inhibitor that targets the base sequence of SEQ ID NO:
- 1 or 2, wherein the TSG6 inhibitor is selected from the group consisting of:
- shRNA comprising the base sequences of SEQ ID Nos. 3 and 4, and
- shRNA comprising the base sequences of SEQ ID Nos. 5 and 6.
A method for treating metastatic solid cancer, the method comprising:
- administering a therapeutically effective amount of a tumor necrosis factor-inducible gene 6 protein (TSG6) inhibitor that targets the base sequence of SEQ ID NO:
- 1 or 2 to a subject in need thereof.
Dependencies are inferred from the claim text.